ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant...

67
ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by: Roberta Clune, Lead Data Manager

Transcript of ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant...

Page 1: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

ACRIN 6698Diffusion-weighted MRI Biomarkers for

Assessment of Breast Cancer Response to Neoadjuvant Treatment:

An I-SPY 2 Trial Substudy

Presented by: Roberta Clune, Lead Data Manager

Page 2: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Online

Data Management System:Navigating the ACRIN Website

http:// www.acrin.org

Page 3: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Select the tab titled: Protocol Summary Table

Page 4: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 5: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 6: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 7: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Case Report Forms

Page 8: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Form Completion Instructions

Available on the 6698 Data Forms Website Refer to the General Form Completion

Instructions for a detailed process of ACRIN form completion, submission and revision

Form specific completion instructions also available

Page 9: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 10: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 11: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 12: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 13: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Adverse Event Reporting

For this trial:– Refer to Protocol Section 10.0 for when

and how to report– Please contact the primary Data Manager

of the study to guide you through the reporting process

Page 14: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 15: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 16: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Data Center Login

Accessing the Data Center

Web form Data Entry System

Page 17: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 18: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Up to 2 unique logins and user passwords will be given to each site prior to patient enrollment. Please contact the 6698 Project Manager, Deb Harbison, if this has not been provided.

Page 19: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 20: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 21: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 22: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 23: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 24: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Select the View Patient Calendar link to view each participant calendar. The calendar lists all data expected for submission, i.e. data forms, images, and reports when applicable. The calendar is updated upon data submission.

Page 25: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

View Patient Calendar

Page 26: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 27: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 28: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 29: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 30: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Select Data Collection to view forms expected for submission through the ACRIN website

Page 31: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Data Collection

Page 32: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 33: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 34: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Upon submission of the form through the web, the received date is updated and the form is removed from the Data Collection screen. The receipt of the form is also updated within the View Calendar screen.

Example: study 6685

Page 35: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Error message boxes appear specific to: Mandatory values Validity Checks Date Discrepancies

Processing a form Submit: processes the form Clear: will clear the form Delete: will delete the current form and return to previous page

Email confirmation is sent upon successful form submission

Online Entry Tips

Page 36: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Site Ops Tool

View listings of outstanding or projected forms on calendars across a study or case.

Page 37: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 38: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 39: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 40: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Example of study 6682

Form Occurrence

Single: A form code that may appear several times on the participant calendar but each with an individual due date. (Ex: TM form)

Multiple: A form code that appears once on the participant calendar but with multiple case records contained within the form. Each case record has an individual due date (Ex. AE form)

Page 41: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 42: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 43: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Forms Due Report

Page 44: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Request for outstanding data

Encourage prompt submission of data, reports, and images

Affords an opportunity to resolve discrepancies between the Institution's records and the Data Management Center

A listing of each item that has not been received by a specified deadline

Sent to the PI and RA of record for a protocol

Can be run by the site through the SiteOps tool

Forms Due Report

Page 45: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 46: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Generated when:– Inconsistencies exist– Confirmation of data entered is necessary– Mandatory data fields are incomplete

– E-mailed to site RA– Protocol, case, form, question specific– Due Date is the date query is sent to the site– Respond in timely manner

Data Queries

Page 47: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Z1: Request for Additional Information

Page 48: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Revise-It http://www.acrin.org

Page 49: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 50: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 51: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 52: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 53: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 54: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Example: study 4701

Page 55: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Revise to “No”

Please Note: •When revising incorrect data, checks are in place (future dates, ranges, etc. that could generate a query)

Page 56: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 57: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

• Query Response: • Applies to a Z1• Applies to a ZW (Excel spreadsheet)

• Site Revision: • Applies to a random update to a form by the site.

• Audit QC Finding Correction: Applies to data revisions found during a site audit. • Query Response:

• Applies to a Z1• Applies to a ZW (Excel spreadsheet)

• Site Revision: • Applies to a random update to a form by the site.

• Audit QC Finding Correction: Applies to data revisions found during a site audit.

Page 58: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

• If “Query Response” is selected, a prompt will appear instructing users to select the appropriate/corresponding query.

• All due dates for outstanding queries for the case will be listed at the bottom of the screen. Check the due date of the query that applies to the revision.

• When finished, select the “Save and Submit” button.

• To cancel revisions, select the “Correct Form” button.

Page 59: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Once revisions are submitted/saved, a confirmation e-mail will be generated which includes two attachments:

•Completed revised form with a version number which will change with subsequent revisions to a form.

•Summary form showing only the changes that were made during that particular session.

•An example of the e-mail and attachments will be presented by ACRIN 6684 on the next couple of slides.

Page 60: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 61: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 62: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:
Page 63: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Additional Information Needed:

•Does not apply to multiple occurring forms (ex: AE). Revisions to these forms must be faxed to ACRIN.

•Remember: When revising data, make sure to correct the source document using GCP guidelines. (Line thru the error, write corrected data, date and initial the change).

•The corrected CRF is required to be sent back to ACRIN.

Page 64: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

GCPs

Good Clinical Practices: Documentation

Page 65: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Incorrect GCP

Page 66: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Correct GCP

Page 67: ACRIN 6698 Diffusion-weighted MRI Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: An I-SPY 2 Trial Substudy Presented by:

Questions ?